Rivista

The efficacy of CHOEP chemotherapyregimenadministered in association with monoclonalantibody anti-CD52 Alemtuzumab in cutaneous T-celllymphoma (CTCL) and systemic T-celllymphoma with cutaneousinvolvement (PTCL)

Autori: Postorino M, De Santis G, Marchesi F, Provenzano I, Franceschini L, Pupo L, Rizzo M, Giannì L, Gumenyuk S, Tonialini L, Fiorelli E, Renzi D, Zizzari A.

Data: 2013

Ambito di interesse: Ematologia

Rivista: (Abstract) 12th International Congress of MalignantLymphoma, Lugano 2013. HematolOncol 2013; 31 (Suppl. 1): 201–270

Potrebbero interessarti anche:

Rivista

Autori:

Data:

Ambito di interesse:

Rivista: DOI:10.1182/blood-2020-139297

Leggi dettagli

Rivista 2,07

“Extracorporeal photochemotherapy in steroid refractory graft-versus-host disease: experience of Policlinico Tor Vergata”.

Autori: Fiorelli E, Lanti A, Docimo F, Adorno G

Data: 2014

Ambito di interesse: PATOLOGIA CLINICA

Rivista: TRANSFUSION AND APHERESIS SCIENCE

Leggi dettagli

Rivista 2.12

“Pulmonary Covid Fibrosis a new pharmaceutic approach”

Autori: Menicagli r

Data: 2020

Ambito di interesse: infettivologia

Rivista: International Journal of Preventive Medicine,

Leggi dettagli

The efficacy of CHOEP chemotherapyregimenadministered in association with monoclonalantibody anti-CD52 Alemtuzumab in cutaneous T-celllymphoma (CTCL) and systemic T-celllymphoma with cutaneousinvolvement (PTCL)

Potrebbero interessarti anche:

“Extracorporeal photochemotherapy in steroid refractory graft-versus-host disease: experience of Policlinico Tor Vergata”.

“Pulmonary Covid Fibrosis a new pharmaceutic approach”

Cosa fare per